Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -65.05% is in line with its 5-year average of -68.94%, around the middle of its 5-year range (-678.43%–260.90%).
As of the fiscal period ended Tuesday, June 30, 2026. 837.58% below its 12-month average of 8.82%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -65.05%.
RETURN ON EQUITY (ROE)
-65.05%
RETURN ON EQUITY (ROE) AVG TTM
8.82%
RETURN ON EQUITY (ROE) AVG 3Y
-66.14%
RETURN ON EQUITY (ROE) AVG 5Y
-68.94%
RETURN ON EQUITY (ROE) AVG 10Y
-71.02%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-837.58%
CURRENT VS 3Y AVG
+1.66%
CURRENT VS 5Y AVG
+5.65%
CURRENT VS 10Y AVG
+8.42%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-54.83%
vs the sector median at left
Seres Therapeutics, Inc.
Market Cap
$27.36M
Return on Equity (ROE)
-65.05%
TTM Avg
8.82%
3Y Avg
-66.14%
5Y Avg
-68.94%
Market Cap
$27.94M
Return on Equity (ROE)
-124.64%
TTM Avg
-100.64%
3Y Avg
-80.07%
5Y Avg
-67.08%
Market Cap
$25.70M
Return on Equity (ROE)
-83.26%
TTM Avg
-46.97%
3Y Avg
-39.40%
5Y Avg
-27.49%
Market Cap
$29.07M
Return on Equity (ROE)
N/A
TTM Avg
78.98%
3Y Avg
134.04%
5Y Avg
114.40%
Market Cap
$28.94M
Return on Equity (ROE)
N/A
TTM Avg
235.31%
3Y Avg
130.43%
5Y Avg
123.26%
Market Cap
$26.70M
Return on Equity (ROE)
-122.19%
TTM Avg
-88.53%
3Y Avg
-83.45%
5Y Avg
-77.50%
Market Cap
$29.74M
Return on Equity (ROE)
-111.81%
TTM Avg
-29.10%
3Y Avg
-257.52%
5Y Avg
159.26%
Market Cap
$29.71M
Return on Equity (ROE)
-117.69%
TTM Avg
-1443.79%
3Y Avg
-971.02%
5Y Avg
-813.57%
Market Cap
$29.83M
Return on Equity (ROE)
-120.40%
TTM Avg
-43.89%
3Y Avg
-83.08%
5Y Avg
-65.54%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | $27.36M | -65.05% | 8.82% | -66.14% | -68.94% |
| aTyr Pharma, Inc. (ATYR)vs › | $27.94M | -124.64% | -100.64% | -80.07% | -67.08% |
| iTonic Holdings Ltd. (ITOC)vs › | $25.70M | -83.26% | -46.97% | -39.40% | -27.49% |
| OneMedNet Corporation (ONMD)vs › | $29.07M | N/A | 78.98% | 134.04% | 114.40% |
| Tevogen Bio Holdings Inc. (TVGN)vs › | $28.94M | N/A | 235.31% | 130.43% | 123.26% |
| InspireMD, Inc. (NSPR)vs › | $26.70M | -122.19% | -88.53% | -83.45% | -77.50% |
| GridAI Technologies Corp. (GRDX)vs › | $29.74M | -111.81% | -29.10% | -257.52% | 159.26% |
| Quantum Cyber N.V. (QUCY)vs › | $29.71M | -117.69% | -1443.79% | -971.02% | -813.57% |
| Context Therapeutics Inc. (CNTX)vs › | $29.83M | -120.40% | -43.89% | -83.08% | -65.54% |
| BeyondSpring Inc. (BYSI)vs › | $30.33M | N/A | 29.33% | 173.42% | 64.03% |
ROE
-65.0%
ROA
-22.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -65.05% |
| 2026-03-31 | -176.98% |
| 2025-12-31 | 12.88% |
| 2025-09-30 | 12.34% |
| 2025-06-30 | 260.90% |
| 2025-03-31 | 144.56% |
| 2024-12-31 | 0.99% |
| 2024-09-30 | -106.51% |
| 2023-06-30 | -678.43% |
| 2022-09-30 | -342.33% |
| 2022-06-30 | -447.32% |
| 2022-03-31 | -107.14% |
| 2021-12-31 | -49.87% |
| 2021-09-30 | -19.25% |
| 2021-06-30 | -130.93% |
| 2021-03-31 | -72.87% |
| 2020-12-31 | -51.00% |
| 2020-09-30 | -47.67% |
| 2018-03-31 | -915.23% |
| 2017-12-31 | -147.25% |
| 2017-09-30 | -100.22% |
| 2017-06-30 | -110.83% |
| 2017-03-31 | -87.35% |
| 2016-12-31 | -69.05% |
| 2016-09-30 | -55.81% |
| 2016-06-30 | -48.91% |
| 2016-03-31 | -35.04% |
| 2015-12-31 | -26.67% |
| 2015-09-30 | -19.50% |
| 2015-06-30 | -34.63% |
| 2015-03-31 | -22.07% |
| 2014-09-30 | -255.42% |
